Jason Carter, MD
Orthopaedic Surgery · Lufkin, TXNPI 1063447407
Payments from drug & device makers
Across 67 payments — averaging $87.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Pylant Medical$1K
- Zimmer Biomet$376
- Smith+Nephew$175
- Pacira Therapeutics, Inc.$153
- Vertex$95
- plus $477 from 14 others
What the payments were for
- Travel & lodging$56510%
- Food & beverage$1,93833%
- Education$3,33657%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 14 | $3,084 |
| Pylant Medical | 10 | $1,480 |
| Zimmer Biomet | 6 | $376 |
| Smith+Nephew | 3 | $175 |
| Pacira Therapeutics, Inc. | 8 | $153 |
| Vertex | 1 | $95 |
| Bioventus LLC | 4 | $93 |
| Johnson & Johnson(2 entities) | 5 | $86 |
| Next Science LLC | 1 | $51 |
| AbbVie | 2 | $48 |
| Orthofix Medical, Inc. | 2 | $37 |
| Sanara Medtech Inc. | 3 | $35 |
| Avanos Medical | 1 | $25 |
| Baxter Healthcare | 1 | $22 |
| Vericel Corporation | 1 | $20 |
| Medtronic | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
| Fidia Pharma USA Inc. | 1 | $10 |
| Ossur Americas, Inc. | 1 | $10 |
| Wound Management Technologies, Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Regeneten$146
- mymobility Platform$141
How this compares
$5,839 in reported general payments places this provider in the 50th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium ErDiclofenac Sodium | 188 | $10,520 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 215 | $3,539 |
| Celecoxib | 44 | $1,041 |
| Tramadol Hcl | 54 | $255 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $168 |
| Ondansetron OdtOndansetron | 14 | $165 |
| Prednisone | 66 | $125 |
| Meloxicam | 36 | $115 |
| Cephalexin | 15 | $24 |
| Penicillin V Potassium | 20 | $19 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Lufkin
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- J Richard EvansonPlano$8.1M
- Stefan KreuzerHouston$7M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Howard HarrisBedford$4.6M
- Tiffany HuynhHouston$4.6M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.